Journal: Obesity Reviews

Article Title: Using adipose‐derived mesenchymal stem cells to fight the metabolic complications of obesity: Where do we stand?

doi: 10.1111/obr.13413

Figure Lengend Snippet: The most relevant preclinical studies pertaining to the therapeutic exploitation of adipose‐derived mesenchymal stem cells (ADMSCs) in the treatment of obesity and its metabolic complications in various animal models

Article Snippet: Rat ADMSCs , Intravenous infusion of ADMSCs through vena caudalis at a dose of 2 × 10 6 /rat , Male Sprague–Dawley rats , 8 weeks , Standard chow diet or HFD for 4 weeks , 8 weeks , No significant difference in body weight , Not defined , The level of glucose and HbA1c was significantly lower. , ADMSCs infusion improved insulin sensitivity in diabetic rats. ADMSCs treatment did not change serum insulin and C‐peptide levels. , ADMSCs repaired islet cells by reducing the Islet cells apoptosis and promoting their revascularization. , After ADMSCs infusion TNF‐α, IL‐1β and IL‐6 concentrations were lower. , ADMSCs increased GLUT4, phosphorylated IRS‐1, PDK1, and PKCζ expressions in the liver. , Hu et al. .

Techniques: Animal Model, Injection, Clinical Proteomics, Suspension, Concentration Assay, Preserving, Expressing, Transplantation Assay